2,501 results on '"Glomerulosclerosis, Focal Segmental"'
Search Results
2. A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
3. Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)
4. Genetic Markers for Focal Segmental Glomerulosclerosis
5. Interview Study of Adult and Child Patients and Parents of Children with Swelling Due to Nephrotic Syndrome. (Prepare-NS)
6. Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)
7. A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)
8. Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children (FSGS pediatric)
9. Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System (FSGSALLAGE)
10. A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
11. Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
12. Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
13. Study of WAL0921 in Patients With Glomerular Kidney Diseases
14. taVNS for FRNS in Children (kidNEY-VNS)
15. A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) (kidNEY-VNS)
16. Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET)
17. Obinutuzumab in Primary FSGS
18. AMPK-activation by Metformin in FSGS: AMP-FSGS (AMP-FSGS)
19. Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 (NEPHROL1)
20. NEPTUNE Match Study (NEPTUNE Match)
21. Nephrotic Syndrome Study Network (NEPTUNE)
22. Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease (RESOLVE)
23. The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) (FOrMe)
24. Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)
25. Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
26. A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS) (PODO)
27. Circulating Factors in Nephrotic Syndrome
28. Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) (HONUS)
29. A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX (PHOENIX)
30. A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
31. LDL-Apheresis for FSGS CardioRenal Outcomes
32. A Study of CCX140-B in Subjects With FSGS
33. PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
34. ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank
35. National Registry of Rare Kidney Diseases (RaDaR)
36. A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147
37. Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
38. Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure (FSGS)
39. A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
40. Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan (ACTION)
41. Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
42. Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis (AURONA™)
43. Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria (PODOCYTE)
44. A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
45. Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
46. Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
47. FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
48. KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis (KORNERSTONE)
49. A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
50. Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis (STEFOG)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.